Bharat Biotech and Alopexx Inc Collaborate on Anti-Microbial Vax Development

Collaborative Efforts in Anti-Microbial Vaccine Development

Anti-microbial vax efforts have taken a significant leap as Bharat Biotech teams up with Alopexx Inc to co-develop and commercialize the proprietary broad-spectrum anti-microbial vaccine, AV0328. This exciting collaboration targets poly N-acetyl glucosamine (PNAG), a crucial substance found on various pathogens, including bacteria, fungi, and parasites.

Details of the Partnership

• The collaboration includes an upfront payment and milestone payments for Alopexx.
• AV0328 has shown effectiveness against 15 different pathogens in pre-clinical studies.
• The recent Phase I trials demonstrate the vaccine's tolerability and effectiveness in eliciting strong immune responses.

Expert Insights

Dr. Krishna Ella, executive chairman of Bharat Biotech, stated the importance of developing vaccines to combat anti-microbial resistance. He emphasized the goal of making solutions accessible in regions of high need.

Meanwhile, Dr. Daniel Vlock, CEO of Alopexx, reflected on how this partnership validates their technology's potential and reinforces their commitment to addressing the urgent need for affordable antimicrobial solutions.

A Next Step Forward

This collaboration between Bharat Biotech and Alopexx Inc represents a landmark effort towards eradicating infectious diseases globally, particularly in low-and middle-income countries. As preclinical studies have shown promising results, both companies are optimistic about AV0328's future impact.